Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-690514是可口服的EGFR 和VEGFR 抑制剂,对于EGFR、HER2和HER4的IC50值分别为5、9 和 60 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,180 | 5日内发货 | ||
5 mg | ¥ 1,990 | 5日内发货 | ||
10 mg | ¥ 3,410 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,660 | 5日内发货 |
产品描述 | BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively. |
靶点活性 | EGFR:5 nM, HER2:20 nM, HER4:60 nM |
体外活性 | BMS-690514 inhibits members of the VEGFR family with IC50 values in the range of 25 to 50 nM. BMS-690514 targets several critical signaling pathways: human epidermal growth factor receptor (HER)/ErbB, angiogenesis signaling through VEGFR2, lymphangiogenesis through VEGFR3, respectively. It also shows activity against VEGFR1, Flt-3, and Lck. Permeability of BMS-690514 in Caco-2 cells is in the intermediate range with a moderate potential to be a P-gp substrate[2]. Non–small cell lung tumor cells with exon 19 deletion (HCC4006, HCC827, and PC9) are highly sensitive to BMS-690514, which inhibits their proliferation with IC50 values of 2 to 35 nM. Tumor cell lines with EGFR gene amplification (DiFi, NCI-H2073, A431) are also highly sensitive to inhibition by BMS-690514. Breast and gastric tumor cell lines that have HER2 gene amplification (N87, SNU-216, AU565, BT474, KPL4, and HCC202) are inhibited with IC50 values of 20 to 60 nM[1]. Tumor cell lines that are dependent on HER2 signaling are also found to be highly sensitive to BMS-690514. |
体内活性 | BMS-690514 can cross the blood–brain barrier with a brain-to-plasma ratio of 1. BMS-690514 has been shown to be efficacious in a broad spectrum of tumor xenografts. At doses that are efficacious and well tolerated in the animal models, BMS-690514 inhibits tumor cell proliferation and tumor blood flow[1]. The preclinical ADME properties of BMS-690514 suggest good oral bioavailability in humans and metabolism by multiple pathways including oxidation and glucuronidation[2]. The oral bioavailability of BMS-690514 is 78% in mice, 100% in rats, 8% in monkeys, and 29% in dogs. |
分子量 | 368.43 |
分子式 | C19H24N6O2 |
CAS No. | 859853-30-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 24 mg/mL (65.14 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7142 mL | 13.5711 mL | 27.1422 mL | 67.8555 mL |
5 mM | 0.5428 mL | 2.7142 mL | 5.4284 mL | 13.5711 mL | |
10 mM | 0.2714 mL | 1.3571 mL | 2.7142 mL | 6.7855 mL | |
20 mM | 0.1357 mL | 0.6786 mL | 1.3571 mL | 3.3928 mL | |
50 mM | 0.0543 mL | 0.2714 mL | 0.5428 mL | 1.3571 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BMS-690514 859853-30-8 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR VEGFR HER inhibit BMS 690514 ErbB-1 Vascular endothelial growth factor receptor Epidermal growth factor receptor Inhibitor BMS690514 HER1 inhibitor